Boston Scientific gets French reimbursement for Taxus

Interventional device developer Boston Scientific has received reimbursement approval from the French government for its Taxus Express2 paclitaxel-eluting coronary stent system.

The approval enables patients to be treated with the Taxus stent system in private clinics and hospitals. The product was previously available in France primarily through public hospitals, said the company.

France represents the second largest market in Europe for coronary artery stents, with approximately 150,000 stents implanted annually. Of these, 55% are implanted in private clinics and hospitals and 45% in public hospitals, according to Natick, MA-based Boston Scientific.

By staff writers
January 29, 2004

Related Reading

Boston Scientific shows uptick in preliminary 2003 results, January 14, 2004

Boston Scientific, NitroMed extend collaboration, January 8, 2004

Boston Scientific gets CE Mark for Liberte, December 30, 2003

Grissom named as Boston Scientific VP, December 10, 2003

Boston Scientific gets panel nod for Taxus, November 21, 2003

Copyright © 2004

Page 1 of 180
Next Page